K drug, aletinib, etc. are to be included in the annual cost of K drug of Shenzhen Medical Insurance Co., Ltd. is only 48000

On November 21, Shenzhen Municipal Bureau of human resources and social security released the publication of the review results of 2018 supplementary selection experts Among them, K drug, aletinib, olapari and other heavy anti-cancer drugs just listed in 2018 The publicity time is from November 21, 2018 to November 29, 2018 This is undoubtedly another great good news! It is understood that the supplementary medical insurance for serious and serious diseases in Shenzhen is a further extension and improvement based on the original basic medical insurance and local supplementary medical insurance in Shenzhen, aiming to reduce the burden of the insured precisely The insured who participate in the supplementary insurance for serious diseases shall enjoy the following two benefits in accordance with the Trial Measures of Shenzhen Municipality for supplementary medical insurance for serious and extra serious diseases and other relevant provisions: Treatment 1: in the same social medical insurance year, the medical expenses incurred by the insured during hospitalization belong to the scope of the social medical insurance catalogue according to the measures of Shenzhen Municipality on social medical insurance and should be paid by themselves (excluding the personal self payment department correspondingly increased according to the provisions of articles 66, 67 and 104 of the measures of Shenzhen Municipality on social medical insurance If the accumulative amount exceeds 10000 yuan, 70% of the excess shall be paid by Shenzhen Branch of Ping an Endowment Insurance Co., Ltd (hereinafter referred to as Ping An insurance), the undertaker, without the maximum payment amount For example, an insured person incurred 480000 yuan of hospitalization medical expenses in a designated hospital in Shenzhen from July 1, 2017 to June 30, 2018 due to liver cancer and 120000 yuan of hospitalization medical expenses in a hospital in Guangzhou after going through referral procedures, totaling 600000 yuan of hospitalization medical expenses, of which 500000 yuan was reimbursed by social medical insurance, and 100000 yuan of personal cash payment was deducted from social medical insurance After 20000 yuan of expenses outside the scope of the insurance catalogue, 70% of the remaining 80000 yuan will be paid by Ping An insurance after deducting the starting line of 10000 yuan, i.e 49000 yuan Treatment 2: in the same year of social medical insurance, if the insured purchases the drugs in the catalogue of supplementary medical insurance drugs for serious and serious diseases (hereinafter referred to as the catalogue) in designated medical institutions and designated retail pharmacies of Shenzhen social medical insurance due to serious and serious diseases, 70% of the expenses shall be paid by Ping An insurance, and the maximum payment shall not exceed 150000 yuan That is to say, the insured participating in the serious illness supplementary insurance can get no more than 150000 reimbursement amount when purchasing the drugs in the catalogue Taking K medicine as an example, its retail price in China is 17918 yuan / 100mg, only 54% of that in the United States and 68% of that in Hong Kong In addition, K medicine has a "3 + 3" conscience medicine donation policy The policy of giving medicine to the patients with minimum living insurance can meet the medical conditions and the corresponding economic conditions The China primary health care foundation can provide assistance to the patients with minimum living insurance up to 24 months' dosage of K medicine, that is to say, the patients with minimum living insurance can use it free of charge; For the low-income patients (the patients confirmed to meet the catastrophic medical expenditure) who meet the medical conditions and the corresponding economic conditions, the China primary health care foundation can provide three courses of treatment for them after three courses of self use, and the foundation can continue to provide three courses of treatment for the follow-up patients for each three courses of self use, with the cumulative time no more than 24 months At present, the indication of drug K approved in China is malignant melanoma, the approved dose is 2mg / kg, once every three weeks: for patients with 50kg or less, 17 times of drugs need to be used in a year, the cost is about 300000, after 3 + 3 charity drug donation, only nine cycles need to be borne, the cost is about 160000, plus 70% of the reimbursement ratio, the final patient only needs to pay 48000, which greatly reduces the patient's cost Medication burden Say nothing more, call Shenzhen medical insurance crazily, hope that the policy can be implemented early and benefit the public!